Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2007

View Archived Issues

University of Buffalo awarded NIH grant for tinnitus research / News in Context

IMP-321, an immunopotentiator, activates human effector cytotoxic cells

QX-314 blocks nociception via TRPV1-mediated cell entry

Vitae and Boehringer Ingelheim to codevelop 11beta-HSD1 inhibitors

Cosmo and Ferring enter licensing agreement for Budesonide MMX

Drug candidate identified in COPD bronchodilator collaboration

Patient enrollment begins in phase III Zyflo trial for COPD

Abraxis and FDA reach agreement through SPA for phase III Abraxane trial

Physician's IND approved for Coramsine in U.S.

Orphan drug designation granted to KNS-760704

Lovaxin C safe for use in cervical cancer

Xanodyne receives license to XP-21510 for menorrhagia

Biovest seeks early approval for BiovaxID

Novel CCR2 antagonist shows in vivo efficacy in models of chronic inflammation

Positive phase IIa results reported for Locteron in hepatitis C

Forest and Gedeon report results from cariprazine phase II trial for schizophrenia

Elvucitabine shows potent anti-HIV activity in phase II

Novel selective D3 antagonist from GSK

CHMP issues negative opinion for extended Zavesca indication: Niemann Pick disease

Viracept license in Europe reinstated by EC

Recent Epix patent imparts new agents for preventing transplant rejection

Novartis Pharma seeks approval of Lucentis in Japan

FDA approves expanded labeling for Merck & Co.'s Januvia

Pfizer to cease sales of Exubera

New therapeutic options for cancer imparted in recent patents

European CHMP issues positive opinion for Atripla in HIV/AIDS; Health Canada gives its approval

Efficacy, tolerability of tapentadol immediate release assessed in acute pain following bunionectomy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 21, 2025.
Coinfections and diversity paint the many shades of HIV cure
BioWorld
We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...
Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis
BioWorld
Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted...
Sino to acquire Lanova and pipeline for up to $950M
BioWorld Asia
Sino Biopharmaceutical Ltd. agreed to fully acquire Lanova Medicines Ltd. by buying an additional 95.09% stake in Lanova at a valuation of up to $950.92 million....